GLP-1 and Intestinal Diseases

Research output: Contribution to journalReviewResearchpeer-review

Documents

Accumulating evidence implicates glucagon-like peptide-1 (GLP-1) to have, beyond glucose maintenance, a beneficial role in the gastrointestinal tract. Here, we review emerging data investigating GLP-1 as a novel treatment for intestinal diseases, including inflammatory bowel diseases, short-bowel syndrome, intestinal toxicities and coeliac disease. Possible beneficial mechanisms for these diseases include GLP-1′s influence on gastric emptying, its anti-inflammatory properties and its intestinotrophic effect. The current knowledge basis derives from the available GLP-1 agonist treatments in experimental animals and small clinical trials. However, new novel strategies including dual GLP-1/GLP-2 agonists are also in development for the treatment of intestinal diseases.
Original languageEnglish
Article number383
JournalBiomedicines
Volume9
Issue number4
Number of pages14
ISSN2227-9059
DOIs
Publication statusPublished - 2021

ID: 259509842